INTRODUCTION
Epstein Barr virus is a γ-herpesvirus, which asymptomatically infects the majority of the human population during childhood and then persists for the lifetime of the host.
EBV persistence requires the establishment of a latent infection within the resting memory B cell compartment (1) , where the viral gene expression is largely limited to the non-coding EBER and BART RNAs, with no expression of protein-coding transcripts; a type of latency sometimes termed Latency 0, which allows the virus to evade host immune-responses (44) . Reactivation from this latent state can be non-productive (i.e. not producing new virus particles) with the additional expression of up to 6 nuclear antigens (EBNAs) and a number of membrane proteins (LMP1, LMP2, and vBcl-2), concommittent with growth-transformation of the cells; the full range of latent gene expression, termed 'latency III', can be observed in tonsillar B cells during primary infection manifest clinically as infectious monucleosis (29) , in post-transplant lymphoproliferative disease (67) , and in lymphoblastoid cell lines (LCL) established following infection in vitro of primary B cells with EBV (46) . Other forms of latency, spanning a spectrum between latency 0 and latency III, are commonly associated with EBV associated malignancies of both lymphoid and epithelial origin (44) .
As with other herpesviruses, EBV-infected cells may in some circumstances reactivate to the lytic virus replication cycle, with the expression of more than 80 viral genes and ultimately the release of infectious virus progeny. In some pathological lesions, lytic infection of B cells (35) where all six EBNAs are produced from a large primary transcript driven from one of two upstream promoters, Cp or Wp. However, following infection of B cells in vitro, the first detectable event is expression of EBNA-LP and EBNA2 only from the Wp promoter within hours of infection, which is followed from day 2 onwards by a decline in Wp activity and an increase in Cp-initiated transcripts encoding EBNA-1,-3A, -3B and 3C in addition to EBNA-LP and EBNA-2. The LMP1, LMP2, and the non-coding EBER transcripts appear relatively late, between 2-4 days after infection. The Qp promoter, which is used to transcribe EBNA1 only in the more restricted latency I and latency II states (e.g. in Burkitt's lymphoma and Hodgkin's disease respectively) is not normally active during the establishment of LCLs from normal B cells in culture. Interestingly, following infection in vitro, every B cell that gains a nuclear viral genome not only activates the latency III growth transformation programme, but then also amplifies the latent genome to an average of 40-50 copies per cell in a poorly defined process that is independent of lytic replication (56) .
In contrast, to B cells, the interaction of EBV with epithelial cells is relatively poorly understood. Early studies showed the presence of the virus in desquamated oropharyngeal epithelial cells of patients with acute IM (54) , which was interpreted to indicate that infection and replication of the virus normally occurs within epithelial cells prior to infection of B cells. Indeed, recent data show the presence of EBV DNA, mRNA and protein in a small subset of tonsillar epithelial cells from healthy, EBV-positive donors (41) . However, some more recent data question the evidence for the replication of EBV, or indeed the presence of the viral genome at all, within the oropharyngeal epithelia of either the asymptomatic host or in patients with IM (22, 27, 37) . Nevertheless, EBV replication has been reported in normal tongue epithelium, suggesting the tongue may be a source of EBV secreted into saliva (60) . EBV lytic replication is indisputably observed in epithelial cells in oral hairy leukoplakia (OHL), a non-malignant epithelial lesion occurring in the tongues of individuals infected with HIV. OHL is characterised by productive EBV replication within the upper-layer epithelial cells undergoing terminal differentiation, apoptosis and desquamation, strongly suggesting that EBV replication in vivo is dependent upon the differentiation state of the epithelial cell (2, 61, 63, 67) .
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The evidence to date suggests that true latency in epithelial cells is only observed in EBV-positive epithelial cell tumours such as nasopharyngeal carcinoma (NPC) and a subset of gastric carcinoma (4, 55) . NPC is a tumour of undifferentiated epithelial cells, has a 100% association with EBV, and typically displays a latency II pattern of viral gene expression; i.e., expression of EBERs and BARTs RNA, Qp-initiated EBNA1, LMP2
and, in a subset of tumours, LMP1. These tumours contain high numbers (>40 per cell) of latent viral episomes (53); lytic replication rarely seen, and only occurs in a small subset of tumour cells, and is usually abortive (9, 17, 33, 38, 68) .
Examination of early events following in vitro infection of primary epithelial cells and cell lines has previously been difficult because these CD21 -cells are generally refractory to infection with EBV. Gene-transfection of CD21 into epithelial lines permits efficient infection of these cells, and apparently results in abortive lytic infection (28, 30) .
Some rare clones retaining EBV may be isolated with difficulty by limiting dilution cloning (28) , or the use of recombinant EBV allows drug resistance selection of EBVpositive clones (25) . EBV-positive clones emerging from such experiments typically displayed a latency I or II type gene expression, similar to the EBV expression in the malignant cells of undifferentiated nasopharyngeal carcinoma (4).
Recently, we developed a system where EBV is efficiently delivered into epithelial cells by a more physiological process involving transfer from the surface of virus-loaded resting B cells (52) . EBV binding to B cells is efficient by virtue of the virally encoded gp350 interacting with cell surface CD21, the EBV receptor. However binding of EBV to epithelial cells, which lack expression of CD21, is very inefficient.
We have previously shown that a considerable enhancement of epithelial infection can be achieved using a gp350-knockout recombinant virus and that transfer of B cell-bound EBV to epithelial cells also appears to overcome this barrier. This suggests that not only does gp350 inhibit binding of EBV to epithelial cells, but also initial binding of EBV to B cells via the gp350-CD21 interaction may expose further ligands on the viral membrane, enabling an increase in EBV binding and entry into epithelial cells. Although a definitive explanation for the phenomenon of transfer infection remains to be resolved, it is likely that it has relevance for infection of epithelial cells in vivo.
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The ability to achieve efficient infection of all epithelial cell lines tested, allows early infection events to be carefully investigated qualitatively and quantitatively in sufficiently high numbers of cells without reverting to any drug selection to select rare infected clones able to maintain the EBV genome. This paper reports the results of such an investigation that was designed to address a number of fundamental questions: (i) 
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In (Fig 1C) . We have previously shown that that every primary B cell receiving a viral genome in its nucleus will express EBNA2 and go on to express the full set of growth transforming genes (51). However we do not know if every genome within the nucleus of an epithelial cell will fire or what it will express in the first few days of infection. (66), and tethers these genomes to cellular metaphase chromosomes through chromosome-binding domains or AT hooks (32, 49, 50) . It is therefore not surprising that, in the absence of significant EBNA1 expression, the viral genome is unable to tether to the host chromosomes and is rapidly lost during cellular replication.
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